Across TCGA pan-cancer cohorts, SLC51B mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SLC51B data layer compared with 28 for mass-spec protein and 1 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SLC51B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SLC51B expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.
CCRCC are the cancer types where SLC51B mass-spec protein most reproducibly stratifies survival.